remoxipride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sulpiride derivatives and analogues | 2365 | 80125-14-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.30 | g | O |
| 0.30 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.65 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.16 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.50 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 40.77 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1990 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AL04 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Benzamides |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.44 | acidic |
| pKa2 | 9.09 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | IC50 | 6.06 | CHEMBL | KEGG DRUG | |||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.26 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Kd | 5.40 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.51 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 7.16 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 5.41 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | IC50 | 5.85 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 6.06 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | Ki | 5.34 | CHEMBL | |||||
| Dopamine receptor | GPCR | IC50 | 5.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000166887 | NUI |
| D02682 | KEGG_DRUG |
| C0073047 | UMLSCUI |
| CHEBI:92948 | CHEBI |
| CHEMBL22242 | ChEMBL_ID |
| DB00409 | DRUGBANK_ID |
| D017330 | MESH_DESCRIPTOR_UI |
| 54477 | PUBCHEM_CID |
| 5197 | INN_ID |
| 117591-79-4 | SECONDARY_CAS_RN |
| 0223RD59PE | UNII |
| 235832 | RXNORM |
| 004031 | NDDF |
| 004032 | NDDF |
| 349884002 | SNOMEDCT_US |
| 419361008 | SNOMEDCT_US |
| CHEMBL3989556 | ChEMBL_ID |
| CHEMBL1899328 | ChEMBL_ID |
Pharmaceutical products:
None